$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

$kpti Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000110465914057869 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$21.00K	$21.00K	$133.0K
YoY Change		-84.21%	-75.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.810M	$3.310M	$940.0K
YoY Change	141.14%	252.13%
% of Gross Profit
Research & Development	$15.95M	$13.16M	$6.060M
YoY Change	106.14%	117.15%
% of Gross Profit
Depreciation & Amortization	$100.0K	$50.00K	$40.00K
YoY Change	150.0%	25.0%	-33.33%
% of Gross Profit
Operating Expenses	$19.77M	$16.47M	$7.003M
YoY Change	112.05%	135.17%	53.34%
Operating Profit	-$19.74M	-$16.45M	-$6.870M
YoY Change	111.82%	139.42%	70.3%
Interest Expense	$20.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$20.00K	$17.00K	$1.000K
YoY Change		1600.0%	0.0%
Pretax Income	-$19.72M	-$16.43M	-$6.870M
YoY Change	111.59%	139.16%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$19.72M	-$16.43M	-$6.870M
YoY Change	111.63%	139.17%
Net Earnings / Revenue	-93923.81%	-78242.86%	-5165.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$605.7K	-$553.9K	-$248.9K
COMMON SHARES
Basic Shares Outstanding	32.67M shares	29.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$227.1M	$132.3M	$17.70M
YoY Change	329.3%	647.46%
Cash & Equivalents	$227.1M	$132.3M	$17.67M
Short-Term Investments
Other Short-Term Assets	$4.200M	$3.000M	$500.0K
YoY Change	500.0%	500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$231.3M	$135.3M	$18.20M
YoY Change	331.62%	643.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.734M	$604.0K	$300.0K
YoY Change	1267.0%	101.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$675.0K	$1.392M	$0.00
YoY Change	-67.86%
Total Long-Term Assets	$3.809M	$2.396M	$300.0K
YoY Change	65.61%	698.67%
TOTAL ASSETS
Total Short-Term Assets	$231.3M	$135.3M	$18.20M
Total Long-Term Assets	$3.809M	$2.396M	$300.0K
Total Assets	$235.2M	$137.7M	$18.50M
YoY Change	320.67%	644.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.102M	$3.456M	$1.700M
YoY Change	23.65%	103.29%
Accrued Expenses	$3.649M	$2.003M	$800.0K
YoY Change	92.05%	150.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.234M	$5.647M	$2.500M
YoY Change	55.85%	125.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.100M	$151.0K
YoY Change
Total Long-Term Liabilities	$1.100M	$151.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.234M	$5.647M	$2.500M
Total Long-Term Liabilities	$1.100M	$151.0K	$0.00
Total Liabilities	$7.351M	$5.999M	$2.500M
YoY Change	83.78%	139.96%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$3.000K	$3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$227.8M	$131.7M	$15.90M
YoY Change
Total Liabilities & Shareholders Equity	$235.2M	$137.7M	$18.50M
YoY Change	320.67%	644.21%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$19.72M	-$16.43M	-$6.870M
YoY Change	111.63%	139.17%
Depreciation, Depletion And Amortization	$100.0K	$50.00K	$40.00K
YoY Change	150.0%	25.0%	-33.33%
Cash From Operating Activities	-$16.23M	-$11.88M	-$6.150M
YoY Change	82.36%	93.17%	-22.15%
INVESTING ACTIVITIES
Capital Expenditures	-$2.290M	-$320.0K	$0.00
YoY Change	7533.33%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$2.290M	-$320.0K	$0.00
YoY Change	7533.33%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$112.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	113.3M	-380.0K	23.06M
YoY Change	156.54%	-101.65%	411.31%
NET CHANGE
Cash From Operating Activities	-16.23M	-11.88M	-6.150M
Cash From Investing Activities	-2.290M	-320.0K	0.000
Cash From Financing Activities	113.3M	-380.0K	23.06M
Net Change In Cash	94.82M	-12.58M	16.91M
YoY Change	168.99%	-174.39%	-585.92%
FREE CASH FLOW
Cash From Operating Activities	-$16.23M	-$11.88M	-$6.150M
Capital Expenditures	-$2.290M	-$320.0K	$0.00
Free Cash Flow	-$13.94M	-$11.56M	-$6.150M
YoY Change	57.16%	87.97%	-21.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	844000	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	77000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2003000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1039000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	590000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	435000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	350000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	240000	USD
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	333000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	215000	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	749000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	100000	USD
CY2013Q4	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	698000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	155000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1168000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	36000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	62569000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	92694000	USD
	dei	Entity Registrant Name EntityRegistrantName	Karyopharm Therapeutics Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001503802
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32670103	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2976000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	135283000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1392000	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132307000	USD
CY2014Q2	us-gaap	Assets Assets	137679000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1982000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	157956000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155974000	USD
CY2013Q4	us-gaap	Assets Assets	158226000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3456000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1740000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	79000	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	130000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	305000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5647000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3292000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	224371000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217500000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	131680000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	154934000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137679000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158226000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	21000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13159000	USD
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29720422	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29587258	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29720422	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29587258	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3310000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	16469000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16448000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16431000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29659457	shares
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	133000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6060000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	943000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	7003000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6870000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6869000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2404080	shares
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6869000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	193000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24138000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6214000	USD
	us-gaap	Operating Expenses OperatingExpenses	30352000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30159000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	34000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30125000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.86
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29633215	shares
	us-gaap	Sales Revenue Net SalesRevenueNet	366000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11025000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1822000	USD
	us-gaap	Operating Expenses OperatingExpenses	12847000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12481000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12480000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.39
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2315331	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12480000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	446000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	645000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	652000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	25000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-66000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11313000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	449000	USD
	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	400000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-367000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	5000000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17667000	USD
	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	23557000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	28589000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-23667000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	17276000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-849000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.02
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16431000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30125000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	85000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6734000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	994000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1685000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	629000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-43000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22451000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	22000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	201000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	5999000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3292000	USD
	kpti	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	223000	USD
CY2014Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	29933
CY2014Q1	kpti	Operating Lease Scheduled Rent Payments Due OperatingLeaseScheduledRentPaymentsDue	5600000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P161D
CY2014Q1	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	506000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Contingent Rentals OperatingLeasesRentExpenseContingentRentals	898000	USD
CY2014Q1	kpti	Operating Leases Allowance For Improvements OperatingLeasesAllowanceForImprovements	1000000	USD
CY2014Q1	kpti	Amount Of Operating Lease For Which Allowance For Improvements Is Provided AmountOfOperatingLeaseForWhichAllowanceForImprovementsIsProvided	449000	USD
CY2014Q1	kpti	Annual Interest Rate AnnualInterestRate	0.08	pure
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	400000	USD
CY2014Q1	kpti	Security Deposit Which May Be Reduced In Future SecurityDepositWhichMayBeReducedInFuture	200000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	427000	USD
CY2014Q1	kpti	Lessee Leasing Arrangements Operating Leases Number Of Additional Lease Term LesseeLeasingArrangementsOperatingLeasesNumberOfAdditionalLeaseTerm	1	item
CY2014Q1	kpti	Lessee Leasing Arrangements Operating Leases Additional Extension Term LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm	P5Y

Files In Submission

Name	View Source	Status
0001104659-14-057869-index-headers.html	Edgar Link	pending
0001104659-14-057869-index.html	Edgar Link	pending
0001104659-14-057869.txt	Edgar Link	pending
0001104659-14-057869-xbrl.zip	Edgar Link	pending
a14-14231_110q.htm	Edgar Link	pending
a14-14231_1ex31d1.htm	Edgar Link	pending
a14-14231_1ex31d2.htm	Edgar Link	pending
a14-14231_1ex32d1.htm	Edgar Link	pending
a14-14231_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kpti-20140630.xml	Edgar Link	completed
kpti-20140630.xsd	Edgar Link	pending
kpti-20140630_cal.xml	Edgar Link	unprocessable
kpti-20140630_def.xml	Edgar Link	unprocessable
kpti-20140630_lab.xml	Edgar Link	unprocessable
kpti-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

2014 Q3 Form 10-Q Financial Statement

#000110465914057869 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI Karyopharm Therapeutics Inc. Stock $kpti

2014 Q3 Form 10-Q Financial Statement

#000110465914057869 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti